MYLAN INC. (a Pennsylvania corporation) 3.75% Cash Convertible Notes due 2015 PURCHASE AGREEMENT
Exhibit 1.1
(a Pennsylvania corporation)
3.75% Cash Convertible Notes due 2015
Dated: September 9, 2008
(a Pennsylvania corporation)
$500,000,000
3.75% Cash Convertible Notes due 2015
September 9, 2008
XXXXXXX XXXXX & CO.
Xxxxxxx Lynch, Pierce, Xxxxxx & Xxxxx
Incorporated
Xxxxxxx Lynch, Pierce, Xxxxxx & Xxxxx
Incorporated
Xxxxxxx, Sachs & Co.
as Representatives of the several Initial Purchasers
0 Xxxxx Xxxxxxxxx Xxxxxx
Xxx Xxxx, Xxx Xxxx 00000
as Representatives of the several Initial Purchasers
0 Xxxxx Xxxxxxxxx Xxxxxx
Xxx Xxxx, Xxx Xxxx 00000
Ladies and Gentlemen:
Mylan Inc., a Pennsylvania corporation (the “Company”), confirms its agreement with Xxxxxxx Xxxxx &
Co., Xxxxxxx Lynch, Pierce, Xxxxxx & Xxxxx Incorporated (“Xxxxxxx Xxxxx”), Xxxxxxx, Xxxxx & Co.
(“Xxxxxxx Sachs”) and each of the other Initial Purchasers named in Schedule A hereto
(collectively, the “Initial Purchasers,” which term shall also include any initial purchaser
substituted as hereinafter provided in Section 12 hereof), for whom Xxxxxxx Xxxxx and Xxxxxxx Xxxxx
are acting as representatives (in such capacity, the “Representatives”), with respect to the issue
and sale by the Company and the purchase by the Initial Purchasers, acting severally and not
jointly, of $500,000,000 aggregate principal amount of the Company’s 3.75% Cash Convertible Notes
due 2015 (the “Initial Notes”), and with respect to the grant by the Company to the Initial
Purchasers of the option described in Section 2(b) hereof to purchase all or any part of an
additional $75,000,000 aggregate principal amount of its 3.75% Cash Convertible Notes due 2015 (the
“Option Notes” and together with the Initial Notes, the “Notes”) solely to cover overallotments, if
any. The Notes to be purchased by the Initial Purchasers are to be issued pursuant to an indenture
dated as of September 15, 2008 (the “Indenture”) between the Company, the Guarantors (as defined
below) and The Bank of New York Mellon, as trustee (the “Trustee”). The Notes will be
unconditionally guaranteed on a senior basis (the “Guarantees” and together with the Notes, the
“Securities”) by each of the subsidiaries of the Company listed on the signature page hereto (the
“Guarantors”). Securities issued in book-entry form will be issued to Cede & Co. as nominee of The
Depository Trust Company (“DTC”) pursuant to a letter agreement, to be dated as of Closing Time (as
defined in Section 2(c)), among the Company, the Trustee and DTC (the “DTC Agreement”).
The Company understands that the Initial Purchasers propose to make an offering of the
Securities on the terms and in the manner set forth herein and agrees that the Initial Purchasers
may resell, subject to the conditions set forth herein, all or a portion of the Securities to
purchasers (“Subsequent Purchasers”) at any time after this Agreement has been executed and
delivered. The Securities are to be offered and sold through the Initial Purchasers without being
registered under the Securities Act of 1933, as amended (the “1933 Act”), in reliance upon
exemptions therefrom. Pursuant to the terms of the Securities and the Indenture, investors that
acquire Securities may only resell or otherwise transfer such Securities if such Securities are
hereafter registered under the 1933 Act or if an exemption from the registration requirements of
the 1933 Act is available (including the exemption afforded by Rule 144A (“Rule 144A”)
of the rules and regulations promulgated under the 1933 Act by the Securities and Exchange
Commission (the “Commission”)).
The Company has prepared and delivered to each Initial Purchaser copies of a preliminary
offering memorandum dated September 9, 2008 (the “Preliminary Offering Memorandum”) and has
prepared and will deliver to each Initial Purchaser, on the date hereof or the next succeeding day,
copies of a final offering memorandum dated September 9, 2008 (the “Final Offering Memorandum”),
each for use by such Initial Purchaser in connection with its solicitation of purchases of, or
offering of, the Securities in the manner contemplated by this Agreement. “Offering Memorandum”
means, with respect to any date or time referred to in this Agreement, the most recent offering
memorandum (whether the Preliminary Offering Memorandum or the Final Offering Memorandum, or any
amendment or supplement to either such document), including exhibits thereto and any documents
incorporated therein by reference, which has been prepared and delivered by the Company to the
Initial Purchasers in connection with their solicitation of purchases of, or offering of, the
Securities.
All references in this Agreement to financial statements and schedules and other information
which is “contained,” “included” or “stated” in the Offering Memorandum (or other references of
like import) shall be deemed to mean and include all such financial statements and schedules and
other information which are incorporated by reference in the Offering Memorandum; and all
references in this Agreement to amendments or supplements to the Offering Memorandum shall be
deemed to mean and include the filing of any document under the Securities Exchange Act of 1934
(the “1934 Act”) which is incorporated by reference in the Offering Memorandum.
SECTION 1. Representations and Warranties.
(a) Representations and Warranties. The Company and Guarantors jointly and severally
represent and warrant to each Initial Purchaser as of the date hereof, the Applicable Time referred
to in Section a(i) hereof and the Closing Time referred to in Section 2(c) hereof, and agrees with
each Initial Purchaser, as follows:
(i) Disclosure Package and Final Offering Memorandum. As of the Applicable
Time, neither (x) the Offering Memorandum as supplemented by the final pricing term sheet,
in the form attached hereto as Schedule B (the “Pricing Supplement”), that has been prepared
and delivered by the Company to the Initial Purchasers in connection with their solicitation
of offers to purchase Securities, all considered together (collectively, the “Disclosure
Package”), nor (y) any individual Supplemental Offering Materials (as defined below), when
considered together with the Disclosure Package, included any untrue statement of a material
fact or omitted to state any material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading.
“Applicable Time” means 6:00 am (Eastern time) on September 10, 2008 or such other time as
agreed by the Company and the Representatives.
“Supplemental Offering Materials” means any “written communication” (within the meaning
of the 1933 Act Regulations (as defined below)) prepared by or on behalf of the Company, or
used or referred to by the Company, that constitutes an offer to sell or a solicitation of
an offer to buy the Securities other than the Offering Memorandum or amendments or
supplements thereto (including the Pricing Supplement), including, without limitation, any
road show relating to the Securities that constitutes such a written communication.
As of its issue date and as of the Closing Time, the Final Offering Memorandum will not
include an untrue statement of a material fact or omit to state a material fact necessary in
order to
-2-
make the statements therein, in the light of the circumstances under which they were
made, not misleading.
The representations and warranties in this subsection shall not apply to statements in
or omissions from the Disclosure Package or the Final Offering Memorandum made in reliance
upon and in conformity with written information furnished to the Company by any Initial
Purchaser through any Representative expressly for use therein.
(ii) Incorporated Documents. The documents incorporated or deemed to be
incorporated by reference in the Offering Memorandum at the time they were or hereafter are
filed with the Commission complied and will comply in all material respects with the
requirements of the 1934 Act and the rules and regulations of the Commission thereunder (the
“1934 Act Regulations”), and, when read together with the other information in the Offering
Memorandum, at the time the Offering Memorandum was issued and at the Closing Time, did not
and will not contain an untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements therein not misleading.
(iii) Independent Accountants. Deloitte & Touche LLP, the accountants who
certified the financial statements and supporting schedules included or incorporated by
reference in the Disclosure Package and the Final Offering Memorandum are independent public
accountants with respect to the Company and its subsidiaries within the meaning of the 1933
Act and the rules and regulations thereunder (the “1933 Act Regulations”).
(iv) Financial Statements. The financial statements of the Company included
in the Disclosure Package and the Final Offering Memorandum, together with the related
schedules and notes, present fairly the financial position of the Company and its
consolidated subsidiaries at the dates indicated and the results of operations,
stockholders’ equity and cash flows of the Company and its consolidated subsidiaries for the
periods specified; said financial statements have been prepared in conformity with generally
accepted accounting principles (“GAAP”) applied on a consistent basis throughout the periods
involved. The supporting schedules, if any, included in the Disclosure Package and the
Final Offering Memorandum present fairly in accordance with GAAP the information required to
be stated therein. The selected financial data and the summary financial information of the
Company included in the Disclosure Package and the Final Offering Memorandum present fairly
the information shown therein and have been compiled on a basis consistent with that of the
audited financial statements of the Company incorporated by reference in the Disclosure
Package and the Final Offering Memorandum. The combined financial statements, together with
the related notes, for the generic pharmaceutical business of Merck KGaA acquired by the
Company (“Merck Generics”) which are included in the Disclosure Package and the Final
Offering Memorandum were prepared for filing with the SEC on November 1, 2007, and such
financial statements fairly present in all material respects the financial position of Merck
Generics as of the dates indicated and the results of operations, stockholders’ equity and
cash flows of Merck Generics for the periods specified, and the reconciliation of
shareholders’ equity and net income to GAAP of such financial statements complied in all
material respects with the applicable requirements of the Commission. Except as disclosed
in the Disclosure Package and the Final Offering Memorandum, the pro forma financial data of
the Company included in Annex A in the Disclosure Package and the Final Offering Memorandum
have been prepared in accordance with the Commission’s rules and guidelines with respect to
pro forma financial statements and have been properly compiled on such basis; the
assumptions used in the preparation thereof and the adjustments used therein are appropriate
to give effect to the transactions on the dates indicated in the Disclosure Package and the
Final Offering Memorandum.
-3-
(v) Audit Opinion. The Company has not been notified by KPMG Deutsche
Treuhand-Gesellschaft Aktiengesellschaft Wirtschaftsprufungsgesellschaft (“KPMG”) that KPMG
has any reason to believe that their previously issued audit report on the combined
financial statements of Merck Generics as of December 31, 2006 and 2005 and for the three
years ended December 31, 2006 should not be relied upon.
(vi) No Material Adverse Change in Business. Since the respective dates as of
which information is given in the Disclosure Package and the Final Offering Memorandum,
except as otherwise stated therein, (A) there has been no material adverse change in the
condition, financial or otherwise, or in the earnings, business affairs or business
prospects of the Company and its subsidiaries considered as one enterprise, whether or not
arising in the ordinary course of business (a “Material Adverse Effect”), (B) there have
been no transactions entered into by the Company or any of its subsidiaries, other than
those in the ordinary course of business, which are material with respect to the Company and
its subsidiaries considered as one enterprise, and (C) except for regular quarterly
dividends on the Company’s outstanding convertible preferred stock, there has been no
dividend or distribution of any kind declared, paid or made by the Company on any class of
its capital stock.
(vii) Good Standing of the Company. The Company has been duly organized and is
validly existing as a corporation in good standing under the laws of the Commonwealth of
Pennsylvania and has corporate power and authority to own, lease and operate its properties
and to conduct its business as described in the Disclosure Package and the Final Offering
Memorandum and to enter into and perform its obligations under this Agreement; and the
Company is duly qualified as a foreign corporation to transact business and is in good
standing in each other jurisdiction in which such qualification is required, whether by
reason of the ownership or leasing of property or the conduct of business, except where the
failure so to qualify or to be in good standing would not result in a Material Adverse
Effect.
(viii) Good Standing of Subsidiaries. Each Designated Subsidiary (as defined
below) has been duly organized and is validly existing as a corporation or limited liability
company in good standing under the laws of the jurisdiction of its formation, has corporate
or other power and authority to own, lease and operate its properties and to conduct its
business as described in the Disclosure Package and the Final Offering Memorandum and is
duly qualified as a foreign corporation or limited liability company to transact business
and is in good standing in each jurisdiction in which such qualification is required,
whether by reason of the ownership or leasing of property or the conduct of business, except
where the failure so to qualify or to be in good standing would not result in a Material
Adverse Effect; except as otherwise disclosed in the Disclosure Package and the Final
Offering Memorandum, all of the issued and outstanding capital stock of each Designated
Subsidiary has been duly authorized and validly issued, is fully paid and non-assessable and
is owned by the Company, directly or through subsidiaries, free and clear of any security
interest, mortgage, pledge, lien, encumbrance, claim or equity; none of the outstanding shares of capital stock of the Designated Subsidiaries was issued in violation of any
preemptive or similar rights of any securityholder of such Designated Subsidiary.
Designated Subsidiary means (i) for purposes of the representation made on the date hereof,
each (a) each Guarantor and (b) each other direct or indirect subsidiary of the Company that
holds at least 5% of the consolidated total assets of the Company or accounts for at least
5% of the consolidated total revenues of the Company and (ii) for purposes of the
representation made on the Closing Date, each subsidiary of the Company set forth on a
schedule which the Company shall deliver to the Representatives prior to the Closing Date,
which schedule the Company represents and agrees shall list all subsidiaries of
-4-
the Company other than subsidiaries which do not, in the
aggregate, constitute a “significant subsidiary” as defined in Rule 1-02(x) of Regulation
S-X.
(ix) Capitalization. The authorized, issued and outstanding capital stock of
the Company is as set forth in the Disclosure Package and the Final Offering Memorandum in
the column entitled “Actual” under the caption “Capitalization” (except for subsequent
issuances, if any, pursuant to this Agreement, pursuant to reservations, agreements,
employee benefit plans referred to in the Disclosure Package and the Final Offering
Memorandum or pursuant to the exercise of convertible securities or options referred to in
the Disclosure Package and the Final Offering Memorandum). The shares of issued and
outstanding capital stock of the Company have been duly authorized and validly issued and
are fully paid and non-assessable; and none of the outstanding shares of capital stock of
the Company was issued in violation of the preemptive or other similar rights of any
securityholder of the Company.
(x) Authorization of Agreement. This Agreement has been duly authorized,
executed and delivered by the Company and each of the Guarantors.
(xi) Authorization of the Indenture. The Indenture has been duly authorized by
the Company and each of the Guarantors and, when executed and delivered by the Company and
each of the Guarantors (assuming the due authorization, execution and delivery thereof by
the Trustee), will constitute a valid and binding agreement of the Company and each of the
Guarantors, enforceable against the Company and each of the Guarantors in accordance with
its terms, except as the enforcement thereof may be limited by bankruptcy, insolvency
(including, without limitation, all laws relating to fraudulent transfers), reorganization,
moratorium or similar laws affecting enforcement of creditors’ rights generally and except
as enforcement thereof is subject to general principles of equity (regardless of whether
enforcement is considered in a proceeding in equity or at law).
(xii) Authorization of the Notes. The Notes have been duly authorized and,
when executed, authenticated, issued and delivered in the manner provided for in the
Indenture and delivered against payment of the purchase price therefor as provided in this
Agreement, will constitute valid and binding obligations of the Company, enforceable against
the Company in accordance with their terms, except as the enforcement thereof may be limited
by bankruptcy, insolvency (including, without limitation, all laws relating to fraudulent
transfers) reorganization, moratorium or similar laws affecting enforcement of creditors’
rights generally and except as enforcement thereof is subject to general principles of
equity (regardless of whether enforcement is considered in a proceeding in equity or at
law), and will be in the form contemplated by, and entitled to the benefits of, the
Indenture.
(xiii) Authorization of the Guarantees. The Guarantees have been duly
authorized and, when executed, authenticated, issued and delivered in the manner provided
for in the Indenture and delivered against payment of the purchase price therefor as
provided in this Agreement, will constitute valid and binding obligations of the Guarantors,
enforceable against the Guarantors in accordance with their terms, except as the enforcement
thereof may be limited by bankruptcy, insolvency (including, without limitation, all laws
relating to fraudulent transfers) reorganization, moratorium or similar laws affecting
enforcement of creditors’ rights generally and except as enforcement thereof is subject to
general principles of equity (regardless of whether enforcement is considered in a
proceeding in equity or at law), and will be in the form contemplated by, and entitled to
the benefits of, the Indenture.
-5-
(xiv) Description of the Securities and Indenture. The Securities and the
Indenture will conform in all material respects to the respective statements relating
thereto contained in the Disclosure Package and the Final Offering Memorandum and will be in
substantially the respective forms last delivered to the Initial Purchasers prior to the
date of this Agreement.
(xv) Description of Capital Stock. The capital stock of the Company conforms
to all statements relating thereto contained or incorporated by reference in the Disclosure
Package and the Final Offering Memorandum and such description of the capital stock of the
Company accurately describes the rights with respect to such capital stock set forth in the
Certificate of Incorporation and Bylaws.
(xvi) Absence of Defaults and Conflicts. Neither the Company nor any of its
subsidiaries is (a) in violation of its charter or by-laws or (b) in default in the
performance or observance of any obligation, agreement, covenant or condition contained in
any contract, indenture, mortgage, deed of trust, loan or credit agreement, note, lease or
other agreement or instrument to which the Company or any of its subsidiaries is a party or
by which it or any of them may be bound, or to which any of the property or assets of the
Company or any of its subsidiaries is subject (collectively, “Agreements and Instruments”)
except for defaults that would not result in a Material Adverse Effect; and the execution,
delivery and performance of this Agreement, the Indenture and the Securities and any other
agreement or instrument entered into or issued or to be entered into or issued by the
Company in connection with the transactions contemplated hereby or thereby or in the
Disclosure Package and the Final Offering Memorandum and the consummation of the
transactions contemplated herein and in the Disclosure Package and the Final Offering
Memorandum (including the issuance and sale of the Securities and the use of the proceeds
from the sale of the Securities as described in the Disclosure Package and the Final
Offering Memorandum under the caption “Use of Proceeds”) and compliance by the Company and
the Guarantors with their obligations hereunder have been duly authorized by all necessary
corporate or other action and do not and will not, whether with or without the giving of
notice or passage of time or both, conflict with or constitute a breach of, or default or
Repayment Event (as defined below) under, or result in the creation or imposition of any
lien, charge or encumbrance upon any property or assets of the Company or any of its
subsidiaries pursuant to, the Agreements and Instruments except for such conflicts, breaches
or defaults or Repayment Events or liens, charges or encumbrances that, singly or in the
aggregate, would not result in a Material Adverse Effect, nor will such action result in any
violation of (x) the provisions of the charter or by-laws of the Company or any of its
subsidiaries or (y) any applicable law, statute, rule, regulation, judgment, order, writ or
decree of any government, government instrumentality or court, domestic or foreign, having
jurisdiction over the Company or any of its subsidiaries or any of their assets, properties
or operations, except in the case of clause (y) above, any such violations that, singly or
in the aggregate, would not result in a Material Adverse Effect. As used herein, a
“Repayment Event” means any event or condition which gives the holder of any note, debenture
or other evidence of indebtedness (or any person acting on such holder’s behalf) the right
to require the repurchase, redemption or repayment of all or a portion of such indebtedness
by the Company or any of its subsidiaries.
(xvii) Absence of Labor Dispute. No labor dispute with the employees of the
Company or any of its subsidiaries exists or, to the knowledge of the Company, is imminent,
and the Company is not aware of any existing or imminent labor disturbance by the employees
of any of its or any subsidiary’s principal suppliers, manufacturers, customers or
contractors, which, in either case, would result in a Material Adverse Effect.
-6-
(xviii) Compliance with Laws; Absence of Proceedings. Except as described in
the Disclosure Package and the Final Offering Memorandum and except such matters as would
not, singly or in the aggregate, result in a Material Adverse Effect, neither the Company
nor any of its subsidiaries is in violation of any federal, state, local or foreign statute,
law, rule, regulation, ordinance, code, policy or rule of common law or any judicial or
administrative interpretation thereof, including any judicial or administrative order,
consent, decree or judgment. Except as described in the Disclosure Package and the Final
Offering Memorandum, there is no action, suit, proceeding, inquiry or investigation before
or brought by any court or governmental agency or body, domestic or foreign, now pending,
or, to the knowledge of the Company, threatened, against or affecting the Company or any of
its subsidiaries which might result in a Material Adverse Effect, or which might materially
and adversely affect the consummation of the transactions contemplated by this Agreement or
the performance by the Company of its obligations hereunder. The aggregate of all pending
legal or governmental proceedings to which the Company or any of its subsidiaries is a party
or of which any of their respective property or assets is the subject which are not
described in the Disclosure Package and the Final Offering Memorandum, including ordinary
routine litigation incidental to the business, could not reasonably be expected to result in
a Material Adverse Effect.
(xix) Taxes. All United States federal income tax returns of the Company and
its subsidiaries required by law to be filed have been filed or extensions thereof have been
duly requested and all taxes shown by such returns or otherwise assessed, which are due and
payable, have been paid, except assessments against which appeals have been or will be
promptly taken and as to which adequate reserves have been provided or where the failure to
pay would not result in a Material Adverse Effect. The Company and its subsidiaries have
filed all other tax returns that are required to have been filed by them pursuant to
applicable foreign, state, local or other law except insofar as the failure to file such
returns would not result in a Material Adverse Effect, and has paid all taxes due pursuant
to such returns or pursuant to any assessment received by the Company and its subsidiaries,
except for such taxes, if any, as are being contested in good faith and as to which adequate
reserves have been provided or where the failure to pay would not result in a Material
Adverse Effect. The charges, accruals and reserves on the books of the Company in respect
of any income and corporation tax liability for any years not finally determined are
adequate to meet any assessments or re-assessments for additional income tax for any years
not finally determined, except to the extent of any inadequacy that would not result in a
Material Adverse Effect.
(xx) Controls. The Company and its subsidiaries maintain a system of internal
accounting controls sufficient to provide reasonable assurances that (A) transactions are
executed in accordance with management’s general or specific authorization, (B) transactions
are recorded as necessary to permit preparation of financial statements in conformity with
generally accepted accounting principles and to maintain accountability for assets, (C)
access to assets is permitted only in accordance with management’s general or specific
authorization and (D) the recorded accountability for assets is compared with the existing
assets at reasonable intervals and appropriate action is taken with respect to any
differences. Except, in each case, as disclosed under “Risk Factors — We must maintain
adequate internal controls and be able, on an annual basis, to provide an assertion as to
the effectiveness of such controls. Failure to maintain adequate internal controls or to
implement new or improved controls could have a material adverse effect on our business,
financial position and results of operations and could cause the market value of our common
stock to decline” in the Offering Memorandum, the Company maintains disclosure controls and
procedures (as such term is defined in Rule 13a-15(e) under the 0000 Xxx) that comply with
the requirements of the 1934 Act; such disclosure controls and procedures have been
-7-
designed to ensure that material information relating to the Company and its subsidiaries
is made known to the Company’s principal executive officer and principal financial officer
by others within those entities; and such disclosure controls and procedures are effective.
(xxi) Insurance. The Company and its subsidiaries carry or are entitled to the
benefits of insurance, with financially sound and reputable insurers, in such amounts and
covering such risks as is generally maintained by companies of established repute engaged in
the same or similar business, and all such insurance is in full force and effect.
(xxii) Solvency. The Company is, and immediately after the Closing Time will
be, Solvent. As used herein, the term “Solvent” means, with respect to the Company on a
particular date, that on such date (A) the fair market value of the assets of the Company is
greater than the total amount of liabilities (including contingent liabilities) of the
Company, (B) the present fair salable value of the assets of the Company is greater than the
amount that will be required to pay the probable liabilities of the Company on its debts as
they become absolute and matured, (C) the Company is able to realize upon its assets and pay
its debts and other liabilities, including contingent obligations, as they mature, and (D)
the Company does not have unreasonably small capital.
(xxiii) Absence of Manipulation. Neither the Company nor any affiliate of the
Company has taken, nor will the Company or any affiliate take, directly or indirectly, any
action which is designed to or which has constituted or which would be expected to cause or
result in stabilization or manipulation of the price of any security of the Company to
facilitate the sale or resale of the Securities.
(xxiv) Possession of Intellectual Property. Except as described in Disclosure
Package and the Final Offering Memorandum, the Company and its subsidiaries own or possess,
or can acquire on reasonable terms, adequate patents, patent rights, licenses, inventions,
copyrights, know-how (including trade secrets and other unpatented and/or unpatentable
proprietary or confidential information, systems or procedures), trademarks, service marks,
trade names or other intellectual property (collectively, “Intellectual Property”) necessary
to carry on the business now operated by them, and neither the Company nor any of its
subsidiaries has received any notice or is otherwise aware of any infringement of or
conflict with asserted rights of others with respect to any Intellectual Property or of any
facts or circumstances which would render any Intellectual Property invalid or inadequate to
protect the interest of the Company or any of its subsidiaries therein, and which
infringement or conflict (if the subject of any unfavorable decision, ruling or finding) or
invalidity or inadequacy, singly or in the aggregate, would result in a Material Adverse
Effect.
(xxv) Absence of Further Requirements. Except as disclosed in the Disclosure
Package and Final Offering Memorandum and other than registration or qualification under
state securities or blue sky laws in connection with the offer and sale of the Securities,
no filing with, or authorization, approval, consent, license, order, registration,
qualification or decree of, any court or governmental authority or agency is necessary or
required for the performance by the Company of its obligations hereunder, in connection with
the offering, issuance or sale of the Securities hereunder or the consummation of the
transactions contemplated by this Agreement or for the due execution, delivery or
performance of the Indenture by the Company and the Guarantors, except such as have been
already obtained.
(xxvi) Possession of Licenses and Permits. Except as described in the
Disclosure Package and Final Offering Memorandum, the Company and its subsidiaries possess
such
permits, licenses, approvals, consents and other authorizations (collectively,
“Governmental Licenses”)
-8-
issued by the appropriate federal, state, local or foreign
regulatory agencies or bodies necessary to conduct the business now operated by them, except
where the failure so to possess would not, singly or in the aggregate, result in a Material
Adverse Effect; the Company and its subsidiaries are in compliance with the terms and
conditions of all such Governmental Licenses, except where the failure so to comply would
not, singly or in the aggregate, result in a Material Adverse Effect; all of the
Governmental Licenses are valid and in full force and effect, except where the invalidity of
such Governmental Licenses or the failure of such Governmental Licenses to be in full force
and effect would not, singly or in the aggregate, result in a Material Adverse Effect; and
neither the Company nor any of its subsidiaries has received any notice of proceedings
relating to the revocation or modification of any such Governmental Licenses which, singly
or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would
result in a Material Adverse Effect.
(xxvii) Title to Property. The Company and its subsidiaries have good and
marketable title to all real property owned by the Company and its subsidiaries and good
title to all other properties owned by them, in each case, free and clear of all mortgages,
pledges, liens, security interests, claims, restrictions or encumbrances of any kind except
such as (a) are described in the Disclosure Package and the Final Offering Memorandum or
(b) do not, singly or in the aggregate, materially affect the value of such property and do
not interfere with the use made and proposed to be made of such property by the Company or
any of its subsidiaries; and all of the leases and subleases material to the business of the
Company and its subsidiaries, considered as one enterprise, and under which the Company or
any of its subsidiaries holds properties described in the Disclosure Package and the Final
Offering Memorandum, are in full force and effect, except where the failure of such lease or
sublease to be in full force and effect would not singly or in the aggregate result in a
Material Adverse Effect, and neither the Company nor any of its subsidiaries has any notice
of any material claim of any sort that has been asserted by anyone adverse to the rights of
the Company or any of its subsidiaries under any of the leases or subleases mentioned above,
or affecting or questioning the rights of the Company or any subsidiary thereof to the
continued possession of the leased or subleased premises under any such lease or sublease.
(xxviii) No Cessation By Supplier. Except as would not singly or in the
aggregate have a Material Adverse Effect, no supplier of merchandise to the Company or any
of its subsidiaries has ceased shipments of merchandise to the Company.
(xxix) Related Party Transactions. No relationship, direct or indirect, exists
between or among any of the Company or its subsidiaries or any affiliate of the Company or
its subsidiaries, on the one hand, and any former or current director, officer, stockholder,
customer or supplier of any of them (including any member of their immediate family), on the
other hand, which is required by the 1933 Act or by the 1933 Regulations to be described in
a registration statement on Form S-1 and which is not so described in the Offering
Memorandum.
(xxx) Environmental Laws. Except as described in the Disclosure Package and
the Final Offering Memorandum and except such matters as would not, singly or in the
aggregate, result in a Material Adverse Effect, (A) neither the Company nor any of its
subsidiaries is in violation of any federal, state, local or foreign statute, law, rule,
regulation, ordinance, code, policy or rule of common law or any judicial or administrative
interpretation thereof, including any judicial or administrative order, consent, decree or
judgment, relating to pollution or protection of human health, the environment (including,
without limitation, ambient air, surface water, groundwater, land surface or subsurface
strata) or wildlife, including, without limitation, laws and
regulations relating to the release or threatened release of chemicals, pollutants,
contaminants, wastes, toxic
-9-
substances, hazardous substances, petroleum or petroleum
products, asbestos-containing materials or mold (collectively, “Hazardous Materials”) or to
the manufacture, processing, distribution, use, treatment, storage, disposal, transport or
handling of Hazardous Materials (collectively, “Environmental Laws”), (B) the Company and
its subsidiaries have all permits, authorizations and approvals required under any
applicable Environmental Laws and are each in compliance with their requirements, (C) there
are no pending or, to the Company’s knowledge, threatened administrative, regulatory or
judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or
violation, investigation or proceedings relating to any Environmental Law against the
Company or any of its subsidiaries and (D) there are no events or circumstances that would
reasonably be expected to form the basis of an order for clean-up or remediation, or an
action, suit or proceeding by any private party or governmental body or agency, against or
affecting the Company or any of its subsidiaries relating to Hazardous Materials or
Environmental Laws.
(xxxi) Investment Company Act. The Company is not required, and upon the
issuance and sale of the Securities as herein contemplated and the application of the net
proceeds therefrom as described in the Disclosure Package and the Final Offering Memorandum
will not be required, to register as an “investment company” under the Investment Company
Act of 1940, as amended (the “1940 Act”).
(xxxii) Similar Offerings. Neither the Company nor any of its affiliates, as such
term is defined in Rule 501(b) of Regulation D under the 1933 Act (“Regulation D”) (each, an
“Affiliate”), has, directly or indirectly, solicited any offer to buy, sold or offered to sell
or otherwise negotiated in respect of, or will solicit any offer to buy, sell or offer to sell
or otherwise negotiate in respect of, in the United States or to any United States citizen or
resident, any security which is or would be integrated with the sale of the Securities in a
manner that would require the Securities to be registered under the 1933 Act.
(xxxiii) Rule 144A Eligibility. The Securities are eligible for resale pursuant to
Rule 144A and will not be, at the Closing Time, of the same class as securities listed on a
national securities exchange registered under Section 6 of the 1934 Act or quoted in a U.S.
automated interdealer quotation system.
(xxxiv) No General Solicitation. None of the Company, its Affiliates or any person
acting on its or any of their behalf (other than the Initial Purchasers, as to whom the Company
makes no representation) has engaged or will engage, in connection with the offering of the
Securities, in any form of general solicitation or general advertising within the meaning of
Rule 502(c) of Regulation D.
(xxxv) No Registration Required. Subject to compliance by the Initial Purchasers
with the representations and warranties of the Initial Purchasers and the procedures set forth
in Section 6 hereof, it is not necessary in connection with the offer, sale and delivery of the
Securities to the Initial Purchasers and to each Subsequent Purchaser in the manner contemplated
by this Agreement, the Disclosure Package and the Offering Memorandum to register the Securities
under the 1933 Act or to qualify the Indenture under the Trust Indenture Act of 1939, as amended
(the “1939 Act”).
(b) Officer’s Certificates. Any certificate signed by any officer of the Company or any of
its subsidiaries delivered to the Representatives or to counsel for the Initial Purchasers shall be
deemed a representation and warranty by the Company to each Initial Purchaser as to the matters
covered thereby.
-10-
SECTION 2. Sale and Delivery to Initial Purchasers; Closing.
(a) Initial Notes. On the basis of the representations and warranties herein contained and
subject to the terms and conditions herein set forth, the Company agrees to sell to each Initial
Purchaser, severally and not jointly, and each Initial Purchaser, severally and not jointly, agrees
to purchase from the Company, at a purchase price of 97.75% of their principal amount, the
aggregate principal amount of Initial Notes set forth in Schedule A opposite the name of such
Initial Purchaser, plus any additional principal amount of Initial Notes which such Initial
Purchaser may become obligated to purchase pursuant to the provisions of Section 12 hereof.
(b) Option Notes. In addition, on the basis of the representations and warranties herein
contained and subject to the terms and conditions herein set forth, the Company hereby grants an
option to the Initial Purchasers, severally and not jointly, to purchase $75,000,000 aggregate
principal amount of Option Notes at the same purchase price as the Initial Notes, plus accrued
interest, if any, from the Closing Date to the Additional Closing Time. The option hereby granted
will expire 13 days after the Closing Date and may be exercised in whole or in part from time to
time (but not more than two (2) times without the written consent of the Company) only for the
purpose of covering overallotments which may be made in connection with the offering and
distribution of the Initial Notes upon written notice by the Representatives to the Company setting
forth the principal amount of Option Notes as to which the several Initial Purchasers are then
exercising the option and the time and date of payment and delivery for such Option Notes. Any such
time and date of delivery (each, an “Additional Closing Time”) shall be determined by the
Representatives, but shall not be later than seven full business days after the exercise of said
option, nor in any event prior to the Closing Time, as hereinafter defined. If the option is
exercised as to all or any portion of the Option Notes, each of the Initial Purchasers, acting
severally and not jointly, will purchase that proportion of the aggregate principal amount of
Option Notes then being purchased which the principal amount of Initial Notes set forth in
Schedule A opposite the name of such Initial Purchaser bears to the aggregate principal amount of
Initial Notes.
(c) Payment. Payment of the purchase price for, and delivery of certificates for, the
Securities shall be made at the offices of Xxxxxx Xxxxxx & Xxxxxxx llp, 00 Xxxx Xxxxxx,
Xxx Xxxx, Xxx Xxxx 00000, or at such other place as shall be agreed upon by the Representatives and
the Company, at 9:00 A.M. (Eastern time) on the third (fourth, if the Applicable Time occurs after
4:30 P.M. (Eastern time) on any given day) business day after the date hereof (unless postponed in
accordance with the provisions of Section 12), or such other time not later than ten business days
after such date as shall be agreed upon by the Representatives and the Company (such time and date
of payment and delivery being herein called “Closing Time”).
Payment shall be made to the Company by wire transfer of immediately available funds to a bank
account designated by the Company against delivery to the Representatives for the respective
accounts of the Initial Purchasers of certificates for the Securities to be purchased by them. It
is understood that each Initial Purchaser has authorized the Representatives, for its account, to
accept delivery of, receipt for, and make payment of the purchase price for, the Initial Notes and
the Option Notes, if any, which it has agreed to purchase. Xxxxxxx Xxxxx, individually and not as
representative of the Initial Purchasers, may (but shall not be obligated to) make payment of the
purchase price for the Securities to be purchased by any Initial Purchaser whose funds have not
been received by the Closing Time or the applicable Additional Closing Time, as applicable, but
such payment shall not relieve such Initial Purchaser from its obligations hereunder.
(d) Denominations; Registration. Certificates for the Securities shall be in such
denominations and registered in such names as the Representatives may request in writing at least
one full business
-11-
day before the Closing Time. The Securities will be made available for examination and
packaging by the Representatives in The City of New York not later than 10:00 A.M. (Eastern time)
on the business day prior to the Closing Time.
SECTION 3. Covenants of the Company. The Company covenants with each Initial
Purchaser as follows:
(a) Offering Memorandum. The Company, as promptly as possible, will furnish to each Initial
Purchaser, without charge, such number of copies of the Offering Memorandum and any amendments and
supplements thereto and documents incorporated by reference therein as such Initial Purchaser may
reasonably request.
(b) Notice and Effect of Material Events. The Company will immediately notify
each Initial Purchaser, and confirm such notice in writing, of (x) any filing made
by the Company of information relating to the offering of the Securities with any
securities exchange or any other regulatory body in the United States or any other
jurisdiction (other than, following completion of the placement of the Securities by
the Initial Purchasers, filings in the ordinary course with the Commission and other
regulatory bodies), and (y) prior to the completion of the placement of the offered
Securities by the Initial Purchasers, any material changes in or affecting the
condition, financial or otherwise, or the earnings, business affairs or business
prospects of the Company and its subsidiaries considered as one enterprise which
(i) make any statement in the Disclosure Package, any Offering Memorandum or any
Supplemental Offering Material false or misleading or (ii) are not disclosed in the
Disclosure Package or the Offering Memorandum. In such event or if during such time
any event shall occur as a result of which it is necessary, in the reasonable
opinion of any of the Company, its counsel, the Initial Purchasers or counsel for
the Initial Purchasers, to amend or supplement the Offering Memorandum in order that
the Offering Memorandum not include any untrue statement of a material fact or omit
to state a material fact necessary in order to make the statements therein not
misleading in the light of the circumstances then existing, the Company will
forthwith amend or supplement the Offering Memorandum by preparing and furnishing to
each Initial Purchaser an amendment or amendments of, or a supplement or supplements
to, the Offering Memorandum (in form and substance satisfactory in the reasonable
opinion of counsel for the Initial Purchasers) so that, as so amended or
supplemented, the Offering Memorandum will not include an untrue statement of a
material fact or omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances existing at the time it is
delivered to a Subsequent Purchaser, not misleading.
(c) Amendment and Supplements to the Offering Memorandum; Preparation of Pricing Supplement;
Supplemental Offering Materials. The Company will advise each Initial Purchaser promptly of any
proposal to amend or supplement the Offering Memorandum and will not effect such amendment or
supplement without the consent of the Initial Purchasers; provided, however, that the requirements
of this paragraph (c) shall not apply with respect to the filing of documents under the 1934 Act
after the completion of the sale of Securities by the Initial Purchasers. Neither the consent of
the Initial Purchasers, nor the Initial Purchaser’s delivery of any such amendment or supplement,
shall constitute a waiver of any of the conditions set forth in Section 5 hereof. The Company
represents and agrees that, unless it obtains the prior consent of the Representatives, it has not
made and will not make any offer relating to the Securities by means of any Supplemental Offering
Materials.
-12-
(d) Qualification of Securities for Offer and Sale. The Company will use its best efforts, in
cooperation with the Initial Purchasers, to qualify the Securities for offering and sale under the
applicable securities laws of such states and other jurisdictions as the Initial Purchasers may
designate and to maintain such qualifications in effect as long as required for the sale of the
Securities; provided, however, that the Company shall not be obligated to file any general consent
to service of process or to qualify as a foreign corporation or as a dealer in securities in any
jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing
business in any jurisdiction in which it is not otherwise so subject. The Company will also supply
the Initial Purchasers with such information as is necessary for the determination of the legality
of the Securities for investment under the laws of such jurisdictions as the Initial Purchasers may
request.
(e) DTC. The Company will cooperate with the Initial Purchasers and use its best efforts to
permit the Securities to be eligible for clearance and settlement through the facilities of DTC.
(f) Use of Proceeds. The Company will use the net proceeds received by it from the sale of
the Securities in the manner specified in the Offering Memorandum under “Use of Proceeds”.
(g) Restriction on Sale of Securities. During a period of 90 days from the date of the
Offering Memorandum, the Company will not, without the prior written consent of Xxxxxxx Xxxxx,
directly or indirectly, issue, sell, offer or contract to sell, grant any option for the sale of,
or otherwise transfer or dispose of, any debt securities of the Company.
(h) PORTAL Designation. The Company will use its best efforts to permit the Securities to be
designated PORTAL securities in accordance with the rules and regulations adopted by the Financial
Industry Regulatory Authority (“FINRA”) relating to trading in the PORTAL Market.
(i) Reporting Requirements. Until the offering of the Securities is complete, the Company
will file all documents required to be filed with the Commission pursuant to the 1934 Act within
the time periods required by the 1934 Act and the 1934 Act Regulations.
(j) Restriction on Sale of Common Stock. During a period of 90 days from the date of this
Agreement (the “Lock-Up Period”) , the Company will not, without the prior written consent of
Xxxxxxx Xxxxx, (i) directly or indirectly, offer, pledge, sell, contract to sell, sell any option
or contract to purchase, purchase any option or contract to sell, grant any option, right or
warrant to purchase or otherwise transfer or dispose of any share of Common Stock or any securities
convertible into or exercisable or exchangeable for Common Stock or file any registration statement
under the 1933 Act with respect to any of the foregoing or (ii) enter into any swap or any other
agreement or any transaction that transfers, in whole or in part, directly or indirectly, the
economic consequence of ownership of the Common Stock, whether any such swap or transaction
described in clause (i) or (ii) above is to be settled by delivery of Common Stock or such other
securities, in cash or otherwise. The foregoing sentence shall not apply to the Securities to be
sold hereunder, or to the following:
(i) any transaction involving, including any repurchase, redemption or conversion of, the
Securities;
(ii) the issuance by the Company to its employees or directors of options, warrants or
other rights to purchase Common Stock or other equity awards in shares of Common Stock under any
of the Company’s equity incentive or compensation plans in effect as of the Closing Date;
(iii) any registration statement filed with the SEC on Form S-8 with respect to securities
to be issued pursuant to any employee benefit plan (as defined in Rule 405 under the 1933 Act);
-13-
(iv) any offer, sale, issuance or disposition of Common Stock in connection with the
conversion or payment of dividends and involving the 1.25% Senior Convertible Notes and the
6.50% Mandatory Convertible Preferred Stock, or the filing of a registration statement in
connection with any of the foregoing;
(v) the offer, sale, issuance or disposition of Common Stock in connection with the
conversion of the Company’s 1.25% Senior Convertible Notes and the 6.50% Mandatory Convertible
Preferred Stock, or any transaction pursuant to the convertible hedge transactions or warrant
transactions entered into in connection therewith, or the filing of a registration statement in
connection with any of the foregoing; and
(vi) transactions contemplated by the cash convertible hedge and warrant transactions
described in the Disclosure Package and the Final Offering Memorandum entered into by the
Company in connection with the issuance and sale of the Notes.
SECTION 4. Payment of Expenses.
(a) Expenses. The Company will pay all expenses incident to the performance of its
obligations under this Agreement, including (i) the preparation, printing and delivery of the
Disclosure Package or any Offering Memorandum (including financial statements and any schedules or
exhibits and any document incorporated therein by reference) and of each amendment or supplement
thereto or of any Supplemental Offering Material, (ii) the preparation, printing and delivery to
the Initial Purchasers of this Agreement, any Agreement among Initial Purchasers, the Indenture and
such other documents as may be required in connection with the offering, purchase, sale, issuance
or delivery of the Securities, (iii) the preparation, issuance and delivery of the certificates for
the Securities to the Initial Purchasers, including any transfer taxes, any stamp or other duties
payable upon the sale, issuance or delivery of the Securities to the Initial Purchasers and any
charges of DTC in connection therewith, (iv) the fees and disbursements of the Company’s counsel,
accountants and other advisors, (v) the qualification of the Securities under securities laws in
accordance with the provisions of Section 3(d) hereof, including filing fees and the reasonable
fees and disbursements of counsel for the Initial Purchasers in connection therewith and in
connection with the preparation of the Blue Sky Survey and any supplement thereto, (vi ) the
printing and delivery to the Initial Purchasers of copies of the Blue Sky Survey and any supplement
thereto (vii) the fees and expenses of the Trustee, including the reasonable fees and disbursements
of counsel for the Trustee in connection with the Indenture and the Securities, (viii) the costs
and expenses of the Company relating to investor presentations on any “road show” undertaken in
connection with the marketing of the Securities, including without limitation, expenses associated
with the production of road show slides and graphics, reasonable fees and expenses of any
consultants engaged in connection with the road show presentations, travel and lodging expenses of
the representatives and officers of the Company and any such consultants, and the cost of aircraft
and other transportation chartered in connection with the road show (ix) any fees payable in
connection with the rating of the Securities, (x) the costs and expenses (including without
limitation any damages or other amounts payable in connection with legal or contractual liability)
associated with the reforming of any contracts for sale of the Securities made by the Initial
Purchasers caused by a breach of the representation contained in the sixth paragraph of Section
1(a)(iii), (xi) any fees and expenses payable in connection with the initial and continued
designation of the Securities as PORTAL securities under the PORTAL Market Rules pursuant to FINRA
Rule 5322 and (xii) any fees and expenses payable in connection with the initial and continued
listing of the Securities on any non-U.S. securities exchange. It is understood, however, that
except as provided in this Section 4 and Sections 6, 8 and 9, the Initial Purchasers will pay all
of their own costs and expenses including the fees and expenses of Xxxxxx Xxxxxx & Xxxxxxx
llp, counsel to the Initial Purchasers.
-14-
(b) Termination of Agreement. If this Agreement is terminated by the Representatives in
accordance with the provisions of Section 5 or Section 10(a)(i) or Section 11 hereof, the Company
shall reimburse the Initial Purchasers for all of their out-of-pocket expenses, including the
reasonable fees and disbursements of counsel for the Initial Purchasers.
(c) Allocation of Expenses. The provisions of this Section shall not affect any agreement
that the Company may make for the sharing of such costs and expenses.
SECTION 5. Conditions of Initial Purchasers’ Obligations. The obligations of the
several Initial Purchasers hereunder are subject to the accuracy of the representations and
warranties of the Company and the Guarantors contained in Section 1 hereof or in certificates of
any officer of the Company and the Guarantors or any subsidiary of the Company delivered pursuant
to the provisions hereof, to the performance by the Company and the Guarantors of their covenants
and other obligations hereunder, and to the following further conditions:
(a) Opinion of Counsel for Company. At Closing Time, the Representatives shall have received
the favorable opinion, dated as of Closing Time, of (i) Cravath, Swaine & Xxxxx LLP, special
counsel for the Company, (ii) Xxxxxxx X. Xxxxxxx Esq., Vice President and Global Associate General
Counsel of the Company, and (iii) Xxxx Xxxxx, Esq., Operations Counsel of the Company, in each case
in form and substance satisfactory to counsel for the Initial Purchasers, together with signed or
reproduced copies of such letter for each of the other Initial Purchasers to the effect set forth
in Exhibit A, B and C hereto, respectively. Either such counsel may state that, insofar as such
opinion involves factual matters, such counsel has relied, to the extent such counsel deemed
proper, upon certificates of officers of the Company and its subsidiaries and certificates of
public officials.
(b) Opinion of Counsel for Initial Purchasers. At Closing Time, the Representatives shall
have received the favorable opinion, dated as of Closing Time, of Xxxxxx Xxxxxx & Xxxxxxx llp,
counsel for the Initial Purchasers, together with signed or reproduced copies of such letters
for each of the other Initial Purchasers. Such counsel may also state that, insofar as such
opinion involves factual matters, they have relied, to the extent they deem proper, upon
certificates of officers of the Company and its subsidiaries and certificates of public officials.
(c) Officers’ Certificate. At Closing Time, there shall not have been, since the date hereof
or since the date as of which information is given in the Final Offering Memorandum (exclusive of
any amendments or supplements thereto subsequent to the date of this Agreement), any material
adverse change in the condition, financial or otherwise, or in the earnings, business affairs or
business prospects of the Company and its subsidiaries considered as one enterprise, whether or not
arising in the ordinary course of business, and the Representatives shall have received a
certificate of the President or a Vice President of the Company and of the chief financial or chief
accounting officer of the Company, dated as of Closing Time, to the effect that (i) there has been
no such material adverse change, (ii) the representations and warranties in Section 1 hereof are
true and correct with the same force and effect as though expressly made at and as of Closing Time,
and (iii) the Company has complied with all agreements and satisfied all conditions on its part to
be performed or satisfied at or prior to Closing Time.
(d) Accountants’ Comfort Letter. At the time of the execution of this Agreement, the
Representatives shall have received from Deloitte & Touche LLP a letter dated such date, in form
and substance satisfactory to the Representatives, together with signed or reproduced copies of
such letter for each of the other Initial Purchasers containing statements and information of the
type ordinarily included in accountants’ “comfort letters” to initial purchasers with respect to
the financial statements and certain financial information contained in the Offering Memorandum.
-15-
(e) Bring-down Comfort Letter. At Closing Time, the Representatives shall have received from
Deloitte & Touche LLP a letter, dated as of Closing Time, to the effect that they reaffirm the
statements made in the letter furnished pursuant to subsection (d) of this Section, except that the
specified date referred to shall be a date not more than three business days prior to Closing Time.
(f) Maintenance of Rating. Since the date this Agreement, there shall not have occurred a
downgrading in the rating assigned to the Securities or any of the Company’s other debt securities
by any “nationally recognized statistical rating agency”, as that term is defined by the Commission
for purposes of Rule 436(g)(2) under the 1933 Act, and no such rating agency shall have publicly
announced that it has under surveillance or review, with possible negative implications, its rating
of the Securities or any of the Company’s other debt securities.
(g) PORTAL. At Closing Time, the Securities shall have been designated for trading on PORTAL.
(h) Additional Documents. At the Closing Time, counsel for the Initial Purchasers shall have
been furnished with such documents and opinions as they may require for the purpose of enabling
them to pass upon the issuance and sale of the Securities as herein contemplated, or in order to
evidence the accuracy of any of the representations or warranties, or the fulfillment of any of the
conditions, herein contained; and all proceedings taken by the Company in connection with the
issuance and sale of the Securities as herein contemplated shall be satisfactory in form and
substance to the Representatives and counsel for the Initial Purchasers.
(i) Lock-up Agreements. At the date of this Agreement, the Representatives shall have
received agreements substantially in the form of Exhibit D hereto signed by the persons listed on
Schedule C hereto.
(j) Conditions to Purchase of Option Notes. In the event that the Representatives exercise
their option provided in Section 2(b) hereof to purchase all or any portion of the Option Notes,
the representations and warranties of the Company contained herein and the statements in any
certificates furnished by the Company or any subsidiary of the Company hereunder shall be true and
correct as of each Additional Closing Time and, at the relevant Additional Closing Time, the
Representatives shall have received:
(i) Officers’ Certificate. A certificate, dated such Additional Closing Time,
of the President or a Vice President of the Company and of the chief financial or
chief accounting officer of the Company and each Guarantor confirming that the
certificate delivered at the Closing Time pursuant to Section 5(c) hereof remains
true and correct as of such Additional Closing Time.
(ii) Opinion of Counsel for Company. The favorable opinions, dated as of the
Additional Closing Time, of (i) Cravath, Swaine & Xxxxx LLP, special counsel for the
Company, (ii) Xxxxxxx X. Xxxxxxx, Esq., Corporate Counsel of the Company, and (iii)
Xxxxx X. Xxxxxx, Esq., Corporate Counsel of the Company, in each case, in form and
substance satisfactory to counsel for the Initial Purchasers, dated such Additional
Closing Time, relating to the Option Notes to be purchased on such Additional
Closing Time and otherwise to the same effect as the opinion required by Section
5(a) hereof.
(iii) Opinion of Counsel for the Initial Purchasers. The favorable opinion of
Xxxxxx Xxxxxx & Xxxxxxx llp, counsel for the Initial Purchasers, dated such
Additional
-16-
Closing Time, relating to the Option Notes to be purchased on such Additional
Closing Time and otherwise to the same effect as the opinion required by Section
5(e) hereof.
(iv) Bring-down Comfort Letter. A letter from Deloitte & Touche LLP, in form
and substance satisfactory to the Representatives and dated such Additional Closing
Time, substantially in the same form and substance as the letter furnished to the
Representatives pursuant to Section 5(f) hereof, except that the “specified date” in
the letter furnished pursuant to this paragraph shall be a date not more than five
days prior to such Additional Closing Time.
(v) No Downgrading. Subsequent to the date of this Agreement, no downgrading
shall have occurred in the rating accorded the Securities or any of the Company’s
other debt by any “nationally recognized statistical rating organization,” as that
term is defined by the Commission for purposes of Rule 436(g)(2) under the 1933 Act,
and no such organization shall have publicly announced that it has under
surveillance or review, with possible negative implications, its ratings of any of
the Securities or any of the Company’s other debt.
(k) Termination of Agreement. If any condition specified in this Section shall not have been
fulfilled when and as required to be fulfilled, this Agreement, or, in the case of any condition to
the purchase of Option Notes, at an Additional Closing Time which is after the Closing Time, the
obligations of the several Initial Purchasers to purchase the relevant Option Notes, may be
terminated by the Representatives by notice to the Company at any time at or prior to Closing Time
or such Additional Closing Time, as the case may be, and such termination shall be without
liability of any party to any other party except as provided in Section 4 and except that Sections
1, 7, 8 and 9 shall survive any such termination and remain in full force and effect.
SECTION 6. Subsequent Offers and Resales of the Securities.
(a) No General Solicitation. Each of the Initial Purchasers and the Company hereby establish
and agree that no general solicitation or general advertising (within the meaning of Rule 502(c) of
Regulation D) will be used in the United States in connection with the offering or sale of the
Securities.
(b) Covenants of the Company. The Company covenants with each Initial Purchaser as follows:
(i) Integration. The Company agrees that it will not and will cause its Affiliates
not to, directly or indirectly, solicit any offer to buy, sell or make any offer or sale of, or
otherwise negotiate in respect of, securities of the Company of any class if, as a result of the
doctrine of “integration” referred to in Rule 502 of Regulation D, such offer or sale would
render invalid (for the purpose of (i) the sale of the Securities by the Company to the Initial
Purchasers, (ii) the resale of the offered Securities by the Initial Purchasers to Subsequent
Purchasers or (iii) the resale of the Securities by such Subsequent Purchasers to others) the
exemption from the registration requirements of the 1933 Act provided by Section 4(2) thereof or
by Rule 144A or by Regulation S thereunder or otherwise.
(ii) Rule 144A Information. The Company agrees that, in order to render the
Securities eligible for resale pursuant to Rule 144A under the 1933 Act, while any of the
offered Securities remain outstanding, it will make available, upon request, to any holder of
Securities or prospective purchasers of Securities the information specified in Rule 144A(d)(4),
unless the Company furnishes information to the Commission pursuant to Section 13 or 15(d) of
the 1934 Act.
-17-
(iii) Restriction on Repurchases. Until the expiration of one year after the
original issuance of the Securities, the Company will not, and will cause its affiliates (as
such term is defined under Rule 144(a)(1) under the 0000 Xxx) not to, resell any Securities
which are “restricted securities” (as such term is defined under Rule 144(a)(3) under the
1933 Act), whether as beneficial owner or otherwise (except as agent acting as a securities
broker on behalf of and for the account of customers in the ordinary course of business in
unsolicited broker’s transactions).
(c) Qualified Institutional Buyer. Each Initial Purchaser severally and not jointly
represents and warrants to, and agrees with, the Company that it is a Qualified Institutional Buyer
and an “accredited investor” within the meaning of Rule 501(a) under the 1933 Act (an “Accredited
Investor”).
SECTION 7. Indemnification.
(a) Indemnification of Initial Purchasers. The Company and each Guarantor jointly and
severally agree to indemnify and hold harmless each Initial Purchaser, its affiliates, as such term
is defined in Rule 501(b) of Regulation D (each, an “Affiliate”), its selling agents and each
person, if any, who controls any Initial Purchaser within the meaning of Section 15 of the 1933 Act
or Section 20 of the 1934 Act as follows:
(i) against any and all loss, liability, claim, damage and expense whatsoever, as incurred,
arising out of any untrue statement or alleged untrue statement of a material fact contained in
any preliminary offering memorandum, the Disclosure Package, the Final Offering Memorandum (or
any amendment or supplement thereto) or any Supplemental Offering Materials, or the omission or
alleged omission therefrom of a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading;
(ii) against any and all loss, liability, claim, damage and expense whatsoever, as
incurred, to the extent of the aggregate amount paid in settlement of any litigation, or any
investigation or proceeding by any governmental agency or body, commenced or threatened, or of
any claim whatsoever based upon any such untrue statement or omission, or any such alleged
untrue statement or omission; provided that (subject to Section 7(d) below) any such settlement
is effected with the written consent of the Company; and
(iii) against any and all expense whatsoever, as incurred (including the fees and
disbursements of counsel chosen by the Representatives), reasonably incurred in investigating,
preparing or defending against any litigation, or any investigation or proceeding by any
governmental agency or body, commenced or threatened, or any claim whatsoever based upon any
such untrue statement or omission, or any such alleged untrue statement or omission, to the
extent that any such expense is not paid under (i) or (ii) above;
provided, however, that this indemnity agreement shall not apply to any loss,
liability, claim, damage or expense to the extent arising out of any untrue statement or omission
or alleged untrue statement or omission made in reliance upon and in conformity with written
information furnished to the Company by any Initial Purchaser through any Representative expressly
for use in any preliminary offering memorandum, the Disclosure Package, the Final Offering
Memorandum (or any amendment or supplement thereto) or in any Supplemental Offering Materials.
(b) Indemnification of Company, Guarantors. Each Initial Purchaser severally agrees to
indemnify and hold harmless the Company and the Guarantors and each person, if any, who controls
the Company or the Guarantors, within the meaning of Section 15 of the 1933 Act or Section 20 of
the 1934 Act against any and all loss, liability, claim, damage and expense described in the
indemnity
-18-
contained in subsection (a) of this Section, as incurred, but only with respect to untrue
statements or omissions, or alleged untrue statements or omissions, made in any preliminary
offering memorandum, the Disclosure Package, the Final Offering Memorandum or any Supplemental
Offering Materials in reliance upon and in conformity with written information furnished to the
Company by such Initial Purchaser through any Representative expressly for use therein.
(c) Actions against Parties; Notification. Each indemnified party shall give notice as
promptly as reasonably practicable to each indemnifying party of any action commenced against it in
respect of which indemnity may be sought hereunder, but failure to so notify an indemnifying party
shall not relieve such indemnifying party from any liability hereunder to the extent it is not
materially prejudiced as a result thereof and in any event shall not relieve it from any liability
which it may have otherwise than on account of this indemnity agreement. In the case of parties
indemnified pursuant to Section 7(a) above, counsel to the indemnified parties shall be selected by
Xxxxxxx Xxxxx, and, in the case of parties indemnified pursuant to Section 7(b) above, counsel to
the indemnified parties shall be selected by the Company. An indemnifying party may participate at
its own expense in the defense of any such action; provided, however, that counsel
to the indemnifying party shall not (except with the consent of the indemnified party) also be
counsel to the indemnified party. In no event shall the indemnifying parties be liable for fees
and expenses of more than one counsel (in addition to any local counsel) separate from their own
counsel for all indemnified parties in connection with any one action or separate but similar or
related actions in the same jurisdiction arising out of the same general allegations or
circumstances. No indemnifying party shall, without the prior written consent of the indemnified
parties, settle or compromise or consent to the entry of any judgment with respect to any
litigation, or any investigation or proceeding by any governmental agency or body, commenced or
threatened, or any claim whatsoever in respect of which indemnification or contribution could be
sought under this Section or Section 8 hereof (whether or not the indemnified parties are actual or
potential parties thereto), unless such settlement, compromise or consent (i) includes an
unconditional release of each indemnified party from all liability arising out of such litigation,
investigation, proceeding or claim and (ii) does not include a statement as to or an admission of
fault, culpability or a failure to act by or on behalf of any indemnified party.
(d) Settlement without Consent if Failure to Reimburse. If at any time an indemnified party
shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses
of counsel, such indemnifying party agrees that it shall be liable for any settlement of the nature
contemplated by Section 7(a)(ii) effected without its written consent if (i) such settlement is
entered into more than 45 days after receipt by such indemnifying party of the aforesaid request,
(ii) such indemnifying party shall have received notice of the terms of such settlement at least 30
days prior to such settlement being entered into and (iii) such indemnifying party shall not have
reimbursed such indemnified party in accordance with such request prior to the date of such
settlement.
SECTION 8. Contribution. If the indemnification provided for in Section 7 hereof is
for any reason unavailable to or insufficient to hold harmless an indemnified party in respect of
any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying
party shall contribute to the aggregate amount of such losses, liabilities, claims, damages and
expenses incurred by such indemnified party, as incurred, (i) in such proportion as is appropriate
to reflect the relative benefits received by the Company and the Guarantors on the one hand and the
Initial Purchasers on the other hand from the offering of the Securities pursuant to this Agreement
or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in such
proportion as is appropriate to reflect not only the relative benefits referred to in clause (i)
above but also the relative fault of the Company and the Guarantors on the one hand and of the
Initial Purchasers on the other hand in connection with the statements or omissions which resulted
in such losses, liabilities, claims, damages or expenses, as well as any other relevant equitable
considerations.
-19-
The relative benefits received by the Company and the Guarantors on the one hand and the
Initial Purchasers on the other hand in connection with the offering of the Securities pursuant to
this Agreement shall be deemed to be in the same respective proportions as the total net proceeds
from the offering of the Securities pursuant to this Agreement (before deducting expenses) received
by the Company and the Guarantors and the total underwriting discount received by the Initial
Purchasers, bear to the aggregate initial offering price of the Securities.
The relative fault of the Company and the Guarantors on the one hand and the Initial
Purchasers on the other hand shall be determined by reference to, among other things, whether any
such untrue or alleged untrue statement of a material fact or omission or alleged omission to state
a material fact relates to information supplied by the Company or by the Initial Purchasers and the
parties’ relative intent, knowledge, access to information and opportunity to correct or prevent
such statement or omission.
The Company, the Guarantors and the Initial Purchasers agree that it would not be just and
equitable if contribution pursuant to this Section were determined by pro rata allocation (even if
the Initial Purchasers were treated as one entity for such purpose) or by any other method of
allocation which does not take account of the equitable considerations referred to above in this
Section 8. The aggregate amount of losses, liabilities, claims, damages and expenses incurred by
an indemnified party and referred to above in this Section 8 shall be deemed to include any legal
or other expenses reasonably incurred by such indemnified party in investigating, preparing or
defending against any litigation, or any investigation or proceeding by any governmental agency or
body, commenced or threatened, or any claim whatsoever based upon any such untrue or alleged untrue
statement or omission or alleged omission.
Notwithstanding the provisions of this Section 8, no Initial Purchaser shall be required to
contribute any amount in excess of the amount by which the total price at which the Securities
purchased and sold by it hereunder exceeds the amount of any damages which such Initial Purchaser
has otherwise been required to pay by reason of any such untrue or alleged untrue statement or
omission or alleged omission.
No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the
0000 Xxx) shall be entitled to contribution from any person who was not guilty of such fraudulent
misrepresentation.
For purposes of this Section 8, each person, if any, who controls an Initial Purchaser within
the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act and each Initial
Purchaser’s Affiliates and selling agents shall have the same rights to contribution as such
Initial Purchaser, and each person, if any, who controls the Company or any Guarantor within the
meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act shall have the same rights to
contribution as the Company and the Guarantors. The Initial Purchasers’ respective obligations to
contribute pursuant to this Section 8 are several in proportion to the principal amount of
Securities set forth opposite their respective names in Schedule A hereto and not joint.
SECTION 9. Representations, Warranties and Agreements to Survive. All
representations, warranties and agreements contained in this Agreement or in certificates of
officers of the Company or any of its subsidiaries, or the Guarantors, submitted pursuant hereto
shall remain operative and in full force and effect regardless of (i) any investigation made by or
on behalf of any Initial Purchaser or its Affiliates or selling agents, any person controlling any
Initial Purchaser, its officers or directors or any person controlling the Company or the
Guarantors, and(ii) delivery of and payment for the Securities.
-20-
SECTION 10. Termination of Agreement.
(a) Termination; General. The Representatives may terminate this Agreement, by notice to the
Company, at any time at or prior to Closing Time (i) if there has been, since the time of execution
of this Agreement or since the respective dates as of which information is given in the Preliminary
Offering Memorandum, the Disclosure Package or the Final Offering Memorandum (exclusive of any
amendments or supplements thereto subsequent to the date of this Agreement), any material adverse
change in the condition, financial or otherwise, or in the earnings, business affairs or business
prospects of the Company and its subsidiaries considered as one enterprise, whether or not arising
in the ordinary course of business, or (ii) if there has occurred any material adverse change in
the financial markets in the United States or the international financial markets, any outbreak of
hostilities or escalation thereof or other calamity or crisis or any change or development
involving a prospective change in national or international political, financial or economic
conditions, in each case the effect of which is such as to make it, in the judgment of the
Representatives, impracticable or inadvisable to market the Securities or to enforce contracts for
the sale of the Securities, or (iii) if trading in any securities of the Company has been suspended
or materially limited by the Commission or the New York Stock Exchange, or if trading generally on
the American Stock Exchange or the New York Stock Exchange or in the Nasdaq Global System has been
suspended or materially limited, or minimum or maximum prices for trading have been fixed, or
maximum ranges for prices have been required, by any of said exchanges or by such system or by
order of the Commission, the National Association of Securities Dealers, Inc. or any other
governmental authority, or (iv) a material disruption has occurred in commercial banking or
securities settlement or clearance services in the United States or with respect to Clearstream or
Euroclear Systems in Europe, or (v) if a banking moratorium has been declared by either Federal,
New York or Pennsylvania authorities.
(b) Liabilities. If this Agreement is terminated pursuant to this Section, such termination
shall be without liability of any party to any other party except as provided in Section 4 hereof,
and provided further that Sections 1, 7, 8 and 9 shall survive such termination and remain in full
force and effect.
SECTION 11. Default by the Company.
If the Company shall fail at Closing Time or at the date of delivery to sell the number of
Securities that it is obligated to sell hereunder, then this Agreement shall terminate without any
liability on the part of any nondefaulting party; provided, however, that the provisions of
Sections 1, 4, 7, 8 and 9 shall remain in full force and effect. No action taken pursuant to this
Section 11 shall relieve the Company from liability, if any, in respect of such default.
SECTION 12. Default by One or More of the Initial Purchasers. If one or more of the
Initial Purchasers shall fail at Closing Time or an Additional Closing Time to purchase the
Securities which it or they are obligated to purchase under this Agreement (the “Defaulted
Securities”), the Representative(s) shall have the right, within 24 hours thereafter, to make
arrangements for one or more of the non-defaulting Initial Purchasers, or any other initial
purchasers, to purchase all, but not less than all, of the Defaulted Securities in such amounts as
may be agreed upon and upon the terms herein set forth; if, however, the Representative(s) shall
not have completed such arrangements within such 24-hour period, then:
(a) if the number of Defaulted Securities does not exceed 10% of the aggregate
principal amount of the Securities to be purchased hereunder, each of the non-defaulting
Initial Purchasers shall be obligated, severally and not jointly, to purchase the full
amount thereof in the proportions that their respective underwriting obligations hereunder
bear to the underwriting obligations of all non-defaulting Initial Purchasers, or
-21-
(b) if the number of Defaulted Securities exceeds 10% of the aggregate principal amount
of the Securities to be purchased hereunder, this Agreement shall terminate without
liability on the part of any non-defaulting Initial Purchaser.
No action taken pursuant to this Section shall relieve any defaulting Initial Purchaser from
liability in respect of its default.
In the event of any such default which does not result in a termination of this Agreement,
either the Representatives or, in the case of an Additional Closing Time that is after the Closing
Time, which does not result in a termination of the obligation of the Initial Purchasers to
purchase and the Company to sell the relevant Option Notes, as the case may be, or the Company
shall have the right to postpone Closing Time or the relevant Additional Closing Time, as the case
may be, for a period not exceeding seven days in order to effect any required changes in the
Offering Memorandum or in any other documents or arrangements. As used herein, the term “Initial
Purchaser” includes any person substituted for an Initial Purchaser under this Section 12.
SECTION 13. Tax Disclosure. Notwithstanding any other provision of this Agreement,
immediately upon commencement of discussions with respect to the transactions contemplated hereby,
the Company (and each employee, representative or other agent of the Company) may disclose to any
and all persons, without limitation of any kind, the tax treatment and tax structure of the
transactions contemplated by this Agreement and all materials of any kind (including opinions or
other tax analyses) that are provided to the Company relating to such tax treatment and tax
structure. For purposes of the foregoing, the term “tax treatment” is the purported or claimed
federal income tax treatment of the transactions contemplated hereby, and the term “tax structure”
includes any fact that may be relevant to understanding the purported or claimed federal income tax
treatment of the transactions contemplated hereby.
SECTION 14. Notices. All notices and other communications hereunder shall be in writing and shall
be deemed to have been duly given if mailed or transmitted by any standard form of
telecommunication. Notices to the Initial Purchasers shall be directed to Xxxxxxx Xxxxx, at World
Financial Center, North Tower, 000 Xxxxx Xxxxxx, Xxx Xxxx, Xxx Xxxx 00000, Attention: Xxx
Xxxxxxxx, with a copy to Xxxxxxxx Xxxxxxxxx, Esq., at Xxxxxx Xxxxxx & Xxxxxxx llp, 00 Xxxx
Xxxxxx, Xxx Xxxx, Xxx Xxxx 00000; and notices to the Company shall be directed to Mylan Inc,
0000 Xxxxxxxxx Xxxxx, Xxxxxxxxxx, Xxxxxxxxxxxx 00000, Attention: Xxxxxx X. Xxxxxxxxx, Chief
Financial Officer, with a copy to Xxxxxxx X. Xxxxxx, Esq., at Cravath, Swaine & Xxxxx LLP, 000
Xxxxxx Xxxxxx, Xxx Xxxx, Xxx Xxxx 00000.
SECTION 15. No Advisory or Fiduciary Relationship. The Company and the Guarantors
acknowledge and agree that (a) the purchase and sale of the Securities pursuant to this Agreement,
including the determination of the offering price of the Securities and any related discounts and
commissions, is an arm’s-length commercial transaction between the Company and the Guarantors, on
the one hand, and the several Initial Purchasers, on the other hand, (b) in connection with the
offering contemplated hereby and the process leading to such transaction each Initial Purchaser is
and has been acting solely as a principal and is not the agent or fiduciary of the Company, the
Guarantors, or their respective stockholders, creditors, employees or any other party, (c) no
Initial Purchaser has assumed or will assume an advisory or fiduciary responsibility in favor of
the Company or any Guarantor with respect to the offering contemplated hereby or the process
leading thereto (irrespective of whether such Initial Purchaser has advised or is currently
advising the Company or the Guarantors on other matters) and no Initial Purchaser has any
obligation to the Company or the Guarantors with respect to the offering contemplated hereby except
the obligations expressly set forth in this Agreement, (d) the Initial Purchasers and their
respective affiliates may be engaged in a broad range of transactions that involve interests that
differ from those of the Company and the Guarantors, and (e) the Initial Purchasers have not
provided any legal, accounting,
-22-
regulatory or tax advice with respect to the offering contemplated hereby and the Company and the
Guarantors have consulted their own legal, accounting, regulatory and tax advisors to the extent it
deemed appropriate.
SECTION 16. Integration. This Agreement supersedes all prior agreements and
understandings (whether written or oral) between the Company and the Initial Purchasers, or any of
them, with respect to the subject matter hereof.
SECTION 17. Parties. This Agreement shall inure to the benefit of and be binding upon
the Initial Purchasers, the Company and the Guarantors and their respective successors. Nothing
expressed or mentioned in this Agreement is intended or shall be construed to give any person, firm
or corporation, other than the Initial Purchasers, the Company and the Guarantors and their
respective successors and the controlling persons and officers and directors referred to in
Sections 7 and 8 and their heirs and legal representatives, any legal or equitable right, remedy or
claim under or in respect of this Agreement or any provision herein contained. This Agreement and
all conditions and provisions hereof are intended to be for the sole and exclusive benefit of the
Initial Purchasers, Company and the Guarantors and their respective successors, and said
controlling persons and officers and directors and their heirs and legal representatives, and for
the benefit of no other person, firm or corporation. No purchaser of Securities from any Initial
Purchaser shall be deemed to be a successor by reason merely of such purchase.
SECTION 18. GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.
SECTION 19. TIME. TIME SHALL BE OF THE ESSENCE OF THIS AGREEMENT. EXCEPT AS
OTHERWISE SET FORTH HEREIN, SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME.
SECTION 20. Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be deemed to be an original, but all such counterparts shall
together constitute one and the same Agreement.
SECTION 21. Effect of Headings. The Section headings herein are for convenience only
and shall not affect the construction hereof.
-23-
If the foregoing is in accordance with your understanding of our agreement, please sign and
return to the Company a counterpart hereof, whereupon this instrument, along with all counterparts,
will become a binding agreement between the Initial Purchasers, the Company and the Guarantors in
accordance with its terms.
Very truly yours, MYLAN INC. |
||||
By | /s/ Xxxxxx X. Xxxxxxxxx | |||
Title: Chief Financial Officer | ||||
BERTEK INTERNATIONAL, INC. |
||||
By | /s/ Xxxxxxx Xxxxxxx | |||
Title: Authorized Signatory | ||||
XXX, INC. |
||||
By | /s/ Xxxxxxx Xxxxxxx | |||
Title: Authorized Signatory | ||||
XXX, X.X. |
||||
By | /s/ Xxxxxxx Xxxxxxx | |||
Title: Authorized Signatory | ||||
XXX LIMITED PARTNER, INC. |
||||
By | /s/ Xxxxxxx Xxxxxxx | |||
Title: Authorized Signatory | ||||
EMD, INC. |
||||
By | /s/ Xxxxxxx Xxxxxxx | |||
Title: Authorized Signatory | ||||
-24-
MLRE LLC |
||||
By | /s/ Xxxxxx X. Xxxxxxxxx | |||
Title: Authorized Signatory | ||||
MP AIR INC. |
||||
By | /s/ Xxxxxxx Xxxxxxx | |||
Title: Authorized Signatory | ||||
MYLAN BERTEK PHARMACEUTICALS INC. |
||||
By | /s/ Xxxxxxx Xxxxxxx | |||
Title: Authorized Signatory | ||||
MYLAN CARIBE, INC. |
||||
By | /s/ Xxxxxxx Xxxxxxx | |||
Title: Authorized Signatory | ||||
MYLAN DELAWARE INC. |
||||
By | /s/ Xxxxxxx Xxxxxxx | |||
Title: Authorized Signatory | ||||
MYLAN INC. (A DELAWARE SUBSIDIARY OF THE COMPANY) |
||||
By | /s/ Xxxxxxx Xxxxxxx | |||
Title: Authorized Signatory | ||||
MYLAN LHC INC. |
||||
By | /s/ Xxxxxxx Xxxxxxx | |||
Title: Authorized Signatory | ||||
-25-
MYLAN PHARMACEUTICALS INC. |
||||
By | /s/ Xxxxxxx Xxxxxxx | |||
Title: Authorized Signatory | ||||
MYLAN TECHNOLOGIES INC. |
||||
By | /s/ Xxxxxxx Xxxxxxx | |||
Title: Authorized Signatory | ||||
UDL LABORATORIES, INC. |
||||
By | /s/ Xxxxxxx Xxxxxxx | |||
Title: Authorized Signatory | ||||
-26-
CONFIRMED AND ACCEPTED,
as of the date first above written:
as of the date first above written:
XXXXXXX XXXXX & CO.
XXXXXXX LYNCH, PIERCE, XXXXXX & XXXXX
XXXXXXX LYNCH, PIERCE, XXXXXX & XXXXX
INCORPORATED
XXXXXXX, SACHS & CO.
By: XXXXXXX LYNCH, PIERCE, XXXXXX & XXXXX
INCORPORATED
By | /s/ Xxxxxx Xxxxx | |||
Director | ||||
By: XXXXXXX, XXXXX & CO.
By | /s/ Xxxxxxx, Sachs & Co. | |||
Xxxxxxx, Xxxxx & Co. | ||||
For themselves and as Representatives of the other Initial Purchasers named in Schedule A hereto.
SCHEDULE A
Principal | ||||
Amount of | ||||
Name of Initial Purchaser | Securities | |||
Xxxxxxx Lynch, Pierce, Xxxxxx & Xxxxx Incorporated |
$ | 181,118,000 | ||
Xxxxxxx, Sachs & Co. |
$ | 181,117,000 | ||
Citigroup Global Markets
Inc. |
$ | 35,555,000 | ||
X.X. Xxxxxx Securities
Inc. |
$ | 35,555,000 | ||
Mitsubishi UFJ Securities International
plc |
$ | 13,335,000 | ||
ABN AMRO
Incorporated |
$ | 6,665,000 | ||
Calyon Securities (USA)
Inc. |
$ | 6,665,000 | ||
Commerzbank Capital Markets Corp. |
$ | 6,665,000 | ||
Fifth Third Securities,
Inc. |
$ | 6,665,000 | ||
Mizuho Securities USA
Inc. |
$ | 6,665,000 | ||
NatCity Investments,
Inc. |
$ | 6,665,000 | ||
SunTrust Xxxxxxxx Xxxxxxxx,
Inc. |
$ | 6,665,000 | ||
Scotia Capital (USA) Inc. |
$ | 6,665,000 | ||
Total |
$ | 500,000,000 | ||
Sch. A-1
SCHEDULE B
Term sheet
To preliminary offering memorandum dated September 9, 2008
To preliminary offering memorandum dated September 9, 2008
See Attached.
Sch. B-1
SCHEDULE C
List of Persons Subject to Lock-Up Agreements
Xxxxxx Xxxxxx
Xxxxxx Xxxxxxxxx
Xxxxx Xxxxxxx
Xxxxxx X. Xxxxx
Xxxxxx Xxxxxxxxxx
Xxxx Xxxxxx
Xxxxxxx X. Xxxxx
Xxxxxx X. Maroon
Xxxx Xxxxxxxxxx
Xxx Xxxxx
Xxxxx Xxxxxx
X.X. Xxxx
Xxxxxxx X. Xxxxxxxxxx
Xxxxx Xxxxx
Xxxxxxx Xxxxxx
Xxx Xxxxxx
Xxxxxxx Xxxxx
Xxx Xxxxx
Xxxxxx Xxxxxxxxx
Xxxxx Xxxxxxx
Xxxxxx X. Xxxxx
Xxxxxx Xxxxxxxxxx
Xxxx Xxxxxx
Xxxxxxx X. Xxxxx
Xxxxxx X. Maroon
Xxxx Xxxxxxxxxx
Xxx Xxxxx
Xxxxx Xxxxxx
X.X. Xxxx
Xxxxxxx X. Xxxxxxxxxx
Xxxxx Xxxxx
Xxxxxxx Xxxxxx
Xxx Xxxxxx
Xxxxxxx Xxxxx
Xxx Xxxxx
Sch. C-1
Exhibit A
FORM OF OPINION OF COMPANY’S SPECIAL COUNSEL
TO BE DELIVERED PURSUANT TO
SECTION 5(a)
TO BE DELIVERED PURSUANT TO
SECTION 5(a)
[In a form reasonably acceptable to the Initial Purchasers]
A-1
Exhibit B
FORM OF OPINION OF XXXXXXX XXXXXXX
TO BE DELIVERED PURSUANT TO
SECTION 5(a)
TO BE DELIVERED PURSUANT TO
SECTION 5(a)
[In a form reasonably acceptable to the Initial Purchasers]
B-1
Exhibit C
FORM OF OPINION OF XXXX XXXXX
TO BE DELIVERED PURSUANT
TO SECTION 5(a)
TO BE DELIVERED PURSUANT
TO SECTION 5(a)
[In a form reasonably acceptable to the Initial Purchasers]
C-1
Exhibit D
FORM OF LOCK-UP AGREEMENT
September [ ], 2008
XXXXXXX XXXXX & CO.
Xxxxxxx Lynch, Pierce, Xxxxxx & Xxxxx
Xxxxxxx Lynch, Pierce, Xxxxxx & Xxxxx
Incorporated
XXXXXXX, SACHS & CO.
as Representatives of the several Initial Purchasers to be
named in the within mentioned Purchase Agreement
4 World Financial Center
Xxx Xxxx, Xxx Xxxx 00000
as Representatives of the several Initial Purchasers to be
named in the within mentioned Purchase Agreement
4 World Financial Center
Xxx Xxxx, Xxx Xxxx 00000
Re: Proposed Offering by Mylan Inc.
Ladies and Gentlemen:
The undersigned, a securityholder and an executive officer and/or director of Mylan Inc., a
Pennsylvania corporation (the “Company”), understands that Xxxxxxx Xxxxx & Co., Xxxxxxx
Lynch, Pierce, Xxxxxx & Xxxxx Incorporated (“Xxxxxxx Xxxxx”) and Xxxxxxx, Sachs & Co.
propose to enter into a purchase agreement (the “Purchase Agreement”) with the Company
providing for the offering of the Company’s cash convertible notes due 2015. In recognition of the
benefit that such offering will confer upon the undersigned as a securityholder and/or an executive
officer and/or director of the Company, and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the undersigned agrees with each initial
purchaser to be named in the Purchase Agreement that, during a period of 90 days from the date of
the Purchase Agreement (the “Lock-Up Period”), the undersigned will not, without the prior
written consent of Xxxxxxx Xxxxx, directly or indirectly, (i) offer, pledge, sell, contract to
sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any
option, right or warrant for the sale of, lend or otherwise dispose of or transfer any of the
Company’s common stock or notes or any securities convertible into or exchangeable or exercisable
for the Company’s common stock, whether now owned or hereafter acquired by the undersigned or with
respect to which the undersigned has or hereafter acquires the power of disposition, or file, or
cause to be filed, any registration statement under the Securities Act of 1933, as amended (the
“1933 Act”), with respect to any of the foregoing (collectively, the “Lock-Up
Securities”) or (ii) enter into any swap or any other agreement or any transaction that
transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of
the Lock-Up Securities, whether any such swap or transaction is to be settled by delivery of common
stock, in cash or otherwise.
Notwithstanding the foregoing, if:
(1) during the last 17 days of the Lock-Up Period, the Company issues an earnings release or
material news or a material event relating to the Company occurs; or
D-1
(2) prior to the expiration of the Lock-Up Period, the Company announces that it will release
earnings results or becomes aware that material news or a material event will occur during the
16-day period beginning on the last day of the Lock-Up Period,
the restrictions imposed by this lock-up agreement (this “Lock-Up Agreement”) shall
continue to apply until the expiration of the 18-day period beginning on the issuance of the
earnings release or the occurrence of the material news or material event, as applicable, unless
Xxxxxxx Xxxxx waives, in writing, such extension.
The undersigned hereby acknowledges and agrees that written notice of any extension of the
Lock-Up Period pursuant to the previous paragraph will be delivered by Xxxxxxx Xxxxx to the Company
(in accordance with the terms of the Purchase Agreement) and that any such notice properly
delivered will be deemed to have been given to, and received by, the undersigned. The undersigned
further agrees that, prior to engaging in any transaction or taking any other action that is
subject to the terms of this Lock-Up Agreement during the period from the date of this Lock-Up
Agreement to and including the 34th day following the expiration of the initial Lock-Up Period, it
will give notice thereof to the Company and will not consummate such transaction or take any such
action unless it has received written confirmation from the Company that the Lock-Up Period (as may
have been extended pursuant to the previous paragraph) has expired.
Notwithstanding the foregoing and subject to the conditions below, the undersigned may
transfer the Lock-Up Securities without the prior written consent of Xxxxxxx Xxxxx, (i) as a bona
fide gift or gifts, (ii) to any trust for the direct or indirect benefit of the undersigned or the
immediate family of the undersigned, or (iii) as a distribution to members, limited partners or
stockholders of the undersigned or to the undersigned’s “affiliates” (as such term is defined in
Rule 501 under the 0000 Xxx) or to any investment fund or other entity controlled or managed by the
undersigned; provided that (1) Xxxxxxx Xxxxx receives a signed Lock-Up Agreement for the
balance of the Lock-Up Period from each donee, trustee, distributee or transferee, as the case may
be; (2) any such transfer shall not involve a disposition for value; (3) such transfers are not
required to be reported in any public report or filing with the Securities and Exchange Commission
(other than reports on Form 5), or otherwise; and (4) the undersigned does not otherwise
voluntarily effect any public filing or report regarding such transfer.
For purposes of this Lock-Up Agreement, “immediate family” shall mean any relationship by
blood, marriage or adoption, not more remote than first cousin. The undersigned also agrees and
consents to the entry of stop transfer instructions with the Company’s transfer agent and registrar
against the transfer of the Lock-Up Securities except in compliance with the foregoing
restrictions.
The undersigned hereby represents and warrants that the undersigned has full power and
authority to enter into this Lock-Up Agreement. All authority herein conferred or agreed to be
conferred and any obligations of the undersigned shall be binding upon the successors, assigns,
heirs or personal representatives of the undersigned.
If the Purchase Agreement does not become effective, or if the Purchase Agreement (other than
the provisions thereof which survive termination) shall terminate or be terminated
D-2
prior to payment for and delivery of the notes to be sold thereunder, the undersigned shall be
released from all obligations under this Lock-Up Agreement.
The undersigned understands that Xxxxxxx Xxxxx is entering into the Purchase Agreement and
proceeding with the offering in reliance upon this Lock-Up Agreement.
D-3
This Lock-Up Agreement shall be governed by and construed in accordance with the laws of the
State of New York, without regard to the conflict of laws principles thereof.
Very truly yours, | ||||||
Signature: | ||||||
Print Name: | ||||||
D-4